Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

21 questions · 21 findings · 3 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 4.8%Low 10 · 47.6%Moderate 5 · 23.8%High 5 · 23.8%

LAMA add‐on vs long‐acting beta2‐agonists (LABA) add‐on

Adverse events (all) · adults with asthma not well controlled on ICS

Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).

1 finding from 1 review